TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24612455

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day for at least 3 months (Group 1)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No treatment (Group 2)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Healthy age-matched controls (Group 3)
Number of subjects: 102
Study: 22275272

Group type: EXPERIMENTAL
Intervention: [phenyl‐U‐¹⁴C]‐aclidinium bromide (400 µg, via 5 min infusion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: [glycolyl‐U‐¹⁴C]‐aclidinium bromide (400 µg, via 5 min infusion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Safety and tolerability assessment
Number of subjects: 12
Study: 20370474

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day) taken on awakening
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day) taken at bedtime
Number of subjects: 316
Study: 17645592

Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg)/vitamin B12 (0.4 mg)/vitamin B6 (40 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg)/vitamin B12 (0.4 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vitamin B6 (40 mg) alone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 16030154

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE; 100 mg, i.m., weekly) + 125 microg levonorgestrel (LNG) daily, orally
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE; 100 mg, i.m., weekly) + 125 microg LNG daily, orally + 0.5 mg dutasteride daily, orally
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE; 100 mg, i.m., weekly) + 300 microg/kg acyline twice weekly, s.c.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE; 100 mg, i.m., weekly) + 125 microg LNG daily, orally + 300 microg/kg acyline twice weekly, s.c.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 29
Study: 12871685

Group type: EXPERIMENTAL
Intervention: L-NAME (1mg/Kg bolus and 1mg/Kg/h continuous IV drip for 5h)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Supportive care alone (control group)
Number of subjects: 30
Study: 10348763

Group type: EXPERIMENTAL
Intervention: Amphotericin B in dextrose (78 courses)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Amphotericin B in lipid emulsion (84 courses)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Amphotericin B in dextrose
Number of subjects: 82

Group type: COMPARATOR
Intervention: Amphotericin B in lipid emulsion
Number of subjects: 82
Study: 8605328

Group type: EXPERIMENTAL
Intervention: r‐metHuG‐CSF (5 microg/kg/d subcutaneously)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (chemotherapy alone)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: r‐metHuG‐CSF
Number of subjects: 34
Study: 2010788

Group type: EXPERIMENTAL
Intervention: Dabao (Chinese herb extract)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 396
Study: 7035031

Group type: EXPERIMENTAL
Intervention: Immunization with killed armadillo-derived M. leprae
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunization with killed M. leprae in a mixture with live BCG
Number of subjects: 0
Study: 6147155

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.2 mg kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suxamethonium 1.5 mg kg‐1 (preceded by gallamine 20 mg 2 min earlier)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg kg‐1 to 0.2 mg kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 0
Study: 31688392

Group type: EXPERIMENTAL
Intervention: CYP2D6 pharmacogenetic screening (DG-I)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deviating genotype control arm (DG-C)
Number of subjects: 0
Study: 30305174

Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral emotion regulation module (in different sequences)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 27261988

Group type: EXPERIMENTAL
Intervention: Buddhist walking meditation (WM)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Traditional walking exercise (WE)
Number of subjects: 23
Study: 23669820

Group type: EXPERIMENTAL
Intervention: Doublet pulse stimulus
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Central activation ratio calculation method
Number of subjects: 12

Group type: COMPARATOR
Intervention: 10-pulse train of stimuli
Number of subjects: 12
Study: 21883820

Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 31
Study: 20092835

Group type: EXPERIMENTAL
Intervention: Ketorolac loaded stent
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control stent
Number of subjects: 276
Study: 17586711

Group type: EXPERIMENTAL
Intervention: One-minute intervention consisting of forming a concrete plan of where, when, and how to floss.
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group (received a packet of floss, information, and a flossing guide without the planning intervention).
Number of subjects: 239
Study: 15615737

Group type: EXPERIMENTAL
Intervention: Expectations video group
Number of subjects: 141

Group type: COMPARATOR
Intervention: Anatomy video group
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Patients with previous cataract surgery experience
Number of subjects: 141
Study: 14524022

Group type: EXPERIMENTAL
Intervention: Discrete plasmapheresis and Fraxiparin
Number of subjects: 394
Study: 10566566

Group type: EXPERIMENTAL
Intervention: Preprandial insulin lispro plus sulfonylurea (L + S)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Bedtime neutral protamine Hagedorn (NPH) insulin plus sulfonylurea (N + S)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Preprandial insulin lispro plus bedtime NPH insulin (L + N)
Number of subjects: 423
Study: 8731070

Group type: EXPERIMENTAL
Intervention: Matching adversity (adversity in the most invested domain according to roles and goals questionnaire)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dependency dysfunctional attitudes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Life events
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dysfunctional attitudes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological and social factors
Number of subjects: 0
Study: 1888402

Group type: EXPERIMENTAL
Intervention: ECG interpretation by Accident & Emergency Senior House Officers
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Management of patients based on ECG interpretation
Number of subjects: 279
Study: 6414253

Group type: EXPERIMENTAL
Intervention: Nitroglycerin administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Metoprolol treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Verapamil treatment
Number of subjects: 10
Study: 31095006

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate
Number of subjects: 68

Group type: COMPARATOR
Intervention: Levonorgestrel implant
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Detectable plasma HIV
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Detectable genital shedding before contraceptive initiation
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Higher plasma efavirenz concentrations
Number of subjects: 68
Study: 29097388

Group type: EXPERIMENTAL
Intervention: Combination therapy with thiazide diuretic and β-blocker
Number of subjects: 314
Study: 25245920

Group type: EXPERIMENTAL
Intervention: Multicolumn spinal cord stimulation (SCS)
Number of subjects: 16
Study: 24560012

Group type: EXPERIMENTAL
Intervention: Paclitaxel, carboplatin, and mapatumumab (10 mg/kg or 30 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin (control arm)
Number of subjects: 0
Study: 21184979

Group type: EXPERIMENTAL
Intervention: Live model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remote model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (ate alone)
Number of subjects: 0
Study: 20001998

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Acenocoumarol
Number of subjects: 117
Study: 17479440

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 433

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 433
Study: 15359544

Group type: EXPERIMENTAL
Intervention: Test Dentifrice (1.0% hydrogen peroxide, 0.243% sodium fluoride, sodium tripolyphosphate in a high-cleaning silica base)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Positive Control Dentifrice (hexametaphosphate-containing whitening dentifrice)
Number of subjects: 76
Study: 11606014

Group type: EXPERIMENTAL
Intervention: Low sodium, low chloride diet (LSD)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate diet (NaHCO3)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Normal sodium chloride diet (NSD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (non-EIA subjects)
Number of subjects: 16
Study: 10601174

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CrS) - 6 x (5 g Cr‐H(2)O + 5 g dextrose)/day for 5 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo - 6 x 5 g dextrose/day for 5 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CrS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8954023

Group type: EXPERIMENTAL
Intervention: MK-677 25 mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 1752455

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg four times a day for 8 to 16 weeks
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg twice a day
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo twice a day
Number of subjects: 138
Study: 7042087

Group type: EXPERIMENTAL
Intervention: BCVPP (carmustine, cyclophosphamide, vinblastine, procarbazine, and prednisone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MOPP (mechlorethamine, vincristine, prednisone, and procarbazine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, and DTIC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCVPP
Number of subjects: 0

Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maintenance chemotherapy or BCG immunotherapy
Number of subjects: 0
Study: 31013455

Group type: EXPERIMENTAL
Intervention: Cannabis containing THC (Cann‐CBD; 8 mg THC)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cannabis containing THC with CBD (Cann+CBD; 8 mg THC + 10 mg CBD)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Matched placebo cannabis
Number of subjects: 17
Study: 28816578

Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 0
Study: 27539273

Group type: EXPERIMENTAL
Intervention: Proprietary glycyrrhizin product
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (blank control)
Number of subjects: 12
Study: 24402598

Group type: EXPERIMENTAL
Intervention: Prediction model for de novo stress urinary incontinence (SUI) after vaginal POP surgery
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Prediction model
Number of subjects: 457

Group type: COMPARATOR
Intervention: Colpopexy and Urinary Reduction Efforts trial participants
Number of subjects: 457
Study: 21644184

Group type: EXPERIMENTAL
Intervention: High-threat condition messages about potential negative consequences of pandemic flu
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Coping messages describing the rationale and effectiveness of hand washing
Number of subjects: 84

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly defined)
Number of subjects: 84
Study: 20705784

Group type: EXPERIMENTAL
Intervention: Anesthesiologist-led, nurse-based acute pain service group with patient-controlled analgesia
Number of subjects: 423

Group type: COMPARATOR
Intervention: Control group with IM or IV boluses of opioid analgesia
Number of subjects: 423
Study: 18164119

Group type: EXPERIMENTAL
Intervention: Animation-assisted CPR (AA-CPR)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Dispatcher-assisted CPR (DA-CPR)
Number of subjects: 85
Study: 15733805

Group type: EXPERIMENTAL
Intervention: Self-acceptance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meaning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Closure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comfort with caregiving
Number of subjects: 0
Study: 12851517

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day)
Number of subjects: 328
Study: 10541926

Group type: EXPERIMENTAL
Intervention: Simulation of front‐crawl arm‐pulling action on a computer‐interfaced isokinetic swim bench
Number of subjects: 12

Group type: COMPARATOR
Intervention: Arm cranking on a modified cycle ergometer
Number of subjects: 12
Study: 8672412

Group type: EXPERIMENTAL
Intervention: Bovine serum albumin (BSA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soyabean-protein isolate (< 0.01 g phytic acid/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bovine whey, casein, egg albumen
Number of subjects: 0
Study: 1458074

Group type: EXPERIMENTAL
Intervention: Yuzpe regimen (ethinyloestradiol 100 micrograms plus levonorgestrel 500 micrograms repeated after 12 hours)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Danazol (600 mg repeated after 12 hours)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg single dose)
Number of subjects: 616
Study: 6141730

Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Betaxolol 1%
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 9
Study: 29665714

Group type: EXPERIMENTAL
Intervention: Customized intervention for caregivers
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 102
Study: 29079458

Group type: EXPERIMENTAL
Intervention: ANODAL tDCS
Number of subjects: 12

Group type: COMPARATOR
Intervention: CATHODAL tDCS
Number of subjects: 12

Group type: COMPARATOR
Intervention: SHAM tDCS
Number of subjects: 12
Study: 27149586

Group type: EXPERIMENTAL
Intervention: WalkAide functional electrical stimulation (pulse width, 300 μs; frequency, 33 Hz, 2 hours/d, 3 days/week for 3 months)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional physical therapy exercise program (3 months)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: WalkAide functional electrical stimulation
Number of subjects: 34
Study: 24763370

Group type: EXPERIMENTAL
Intervention: Resistant starch (RS) diet
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Non-starch polysaccharides (NSPs) diet
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Weight-loss (WL) diet
Number of subjects: 14
Study: 22783048

Group type: EXPERIMENTAL
Intervention: CO₂ insufflation
Number of subjects: 142

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 142
Study: 20213794

Group type: EXPERIMENTAL
Intervention: Chemosensory malingerers
Number of subjects: 88

Group type: COMPARATOR
Intervention: Nonmalingerers
Number of subjects: 88
Study: 19003892

Group type: EXPERIMENTAL
Intervention: Swimming
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Golf
Number of subjects: 45

Group type: COMPARATOR
Intervention: Swimming and Golf
Number of subjects: 45
Study: 16471090

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin (40 mg/m² per week for six cycles)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Three-weekly cisplatin (75 mg/m² on days 1, 22, 43, and 64)
Number of subjects: 40
Study: 12364842

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 10669911

Group type: EXPERIMENTAL
Intervention: 1,000 mg/day of citicoline
Number of subjects: 30
Study: 8758141

Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg base/kg over the first 3 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tetracycline (4 mg/kg four times daily)
Number of subjects: 50
Study: 8099637

Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV)
Number of subjects: 714

Group type: COMPARATOR
Intervention: Oral poliovirus vaccine (OPV)
Number of subjects: 714
Study: 2435150

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy regimen (ABV/ADV) including doxorubicin, vinblastine, bleomycin/actinomycin D, vincristine, dacarbazine.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Recombinant alpha interferon
Number of subjects: 18

Group type: COMPARATOR
Intervention: ABV/ADV
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both treatment arms (recombinant alpha interferon and ABV/ADV)
Number of subjects: 18
Study: 30354950

Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg intravenous daily)
Number of subjects: 3298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3298
Study: 26535565

Group type: EXPERIMENTAL
Intervention: Mailed FIT outreach
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Mailed colonoscopy outreach
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Colonoscopy outreach
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: FIT outreach
Number of subjects: 6000
Study: 25611729

Group type: EXPERIMENTAL
Intervention: Standard ribavirin dosing (group 1)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Low and escalating ribavirin dosing (group 2)
Number of subjects: 62
Study: 23212700

Group type: EXPERIMENTAL
Intervention: SOD2Val16Ala polymorphism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GPX1Pro200Leu polymorphism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CATc.66+78C>T polymorphism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TNF‐308G>A polymorphism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PANSS positive and general scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PANSS positive, negative, and general scores, GAF score
Number of subjects: 0
Study: 22226267

Group type: EXPERIMENTAL
Intervention: LGS-on (low glucose suspend feature activated)
Number of subjects: 50

Group type: COMPARATOR
Intervention: LGS-off (low glucose suspend feature deactivated)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: LGS-on
Number of subjects: 50

Group type: COMPARATOR
Intervention: LGS-off
Number of subjects: 50
Study: 19539437

Group type: COMPARATOR
Intervention: CEW Exposure only
Number of subjects: 40

Group type: COMPARATOR
Intervention: Exertion only
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Exertion plus CEW Exposure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Exertion plus additional Exertion
Number of subjects: 40
Study: 16423665

Group type: EXPERIMENTAL
Intervention: Bosentan therapy
Number of subjects: 12
Study: 15266029

Group type: EXPERIMENTAL
Intervention: Pre-dilution on-line haemofiltration (HF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Haemodialysis with dialysate temperature 36.5 degrees C (HD(36.5))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Haemodialysis with dialysate temperature 35.5 degrees C (HD(35.5))
Number of subjects: 12
Study: 11371734

Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (without intraoperative ultrasound)
Number of subjects: 51
Study: 10443129

Group type: EXPERIMENTAL
Intervention: Topical levobunolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7719088

Group type: EXPERIMENTAL
Intervention: Kanggan Zhibao (KGZB) oral liquor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levamisole (control group)
Number of subjects: 0
Study: 2758010

Group type: EXPERIMENTAL
Intervention: Breast-fed full-term infants
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Formula-fed full-term infants (unsupplemented)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Formula-fed preterm infants (unsupplemented)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Formula-fed full-term infants (supplemented)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Breast-milk
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cow's milk formula (unsupplemented)
Number of subjects: 26
Study: 5440736

Group type: EXPERIMENTAL
Intervention: 1·2 mega‐units of aqueous procaine penicillin plus 1·0 g of probenecid given orally immediately prior to injection
Number of subjects: 613

Group type: COMPARATOR
Intervention: 1·2 mega‐units of aqueous procaine penicillin alone
Number of subjects: 613
Study: 31699166

Group type: EXPERIMENTAL
Intervention: Patient self-report using the Behavior Rating Inventory of Executive Function (BRIEF-A)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Proxy-report using the Behavior Rating Inventory of Executive Function (BRIEF-A)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Behavioral Regulation Index scores from BRIEF-A
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Metacognition Index scores from BRIEF-A
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Performance-based measures of executive functioning
Number of subjects: 47
Study: 30074459

Group type: EXPERIMENTAL
Intervention: No midline shift
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: 1-5 mm midline shift
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: 6-10 mm midline shift
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: > 10 mm midline shift
Number of subjects: 892
Study: 27163895

Group type: EXPERIMENTAL
Intervention: Chloroquine 150 mg once daily for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo once daily for 8 weeks
Number of subjects: 0
Study: 24169068

Group type: EXPERIMENTAL
Intervention: Protein-rich meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fasting state
Number of subjects: 10
Study: 22499405

Group type: EXPERIMENTAL
Intervention: Six-month exercise program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 20